The emergence of new, unrecognized pathogens in the xenotransplant recipient is one of the primary concerns about the pig-to-human heart xenotransplantation. A major concern is the possibility of zoonotic diseases developing in the xenotransplant recipient and spreading to the public. Both in the United States and around the world, zoonotic diseases are quite widespread. According to scientists, more than 6 out of every 10 recognized infectious diseases in humans are transferred by animals. While the risk of zoonotic diseases from the donor organ may be allowable for the xenotransplant recipient, the risk of a zoonotic agent with unforeseeable pathogenicity from the xenotransplant recipient to the community at large would an inadmissible public health risk. Citation: Boneva, R. S. (2001, January 14). Infectious Disease Issues in Xenotransplantation. Retrieved from National Library of Medicine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC88959/ Sawyer, B. (2016). Zoonotic Disease
Within minutes after pig-to-human heart xenotransplantation, hyper-acute rejection might occur, resulting in an acute injury to the vascular endothelial cells of the donor organ. Xenoractive antibodies and the complement system appear to be the two primary factors that mediate HAR. Approaches that will prevent HAR include genetically modified pigs and expression of human complement regulatory proteins in the pig. According to studies on immunologic rejection, many genetically engineered pigs were generated to overcome molecular incompatibilities. Eliminating the gene coding for the enzyme a (1-3) will result in the absence of an a (1-3)-Gal epitope in the pig and could significantly decrease the risk of HAR. Pigs and humans exhibit similar human complement regulatory proteins (CRPs), but pig CRPs are not enough to protect pig cells from human complement-mediated injury. Human CRPs (hCRPs) can be introduced to pig cells to inhibit human complement-mediated injury. Researchers hav